A systematic review and meta‐analysis of 18F‐labeled amyloid imaging in Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Briony Waddell¹  Suvankar Pal¹  Jing Ming Yeo²  Zubair Khan³ 

[1] Anne Rowling Regenerative Neurology ClinicUniversity of EdinburghEdinburghUK;College of Medicine and Veterinary MedicineUniversity of EdinburghEdinburghUK;Department of Nuclear MedicineNHS LothianEdinburghUK;

关键词: Alzheimer's;    Dementia;    Amyloid;    Positron emission tomography;    Florbetapir;    Florbetaben;   

DOI  :  10.1016/j.dadm.2014.11.004

来源: DOAJ

【 摘 要 】

Abstract Background Amyloid imaging using fluorine 18–labeled tracers florbetapir, florbetaben, and flutemetamol has recently been reported in Alzheimer's disease (AD). Methods We systematically searched MEDLINE and EMBASE for relevant studies published from January 1980 to March 2014. Studies comparing imaging findings in AD and normal controls (NCs) were pooled in a meta‐analysis, calculating pooled weighted sensitivity, specificity, and diagnostic odds ratio (OR) using the DerSimonian‐Laird random‐effects model. Results Nineteen studies, investigating 682 patients with AD, met inclusion criteria. Meta‐analysis demonstrated a sensitivity of 89.6%, a specificity of 87.2%, and an OR of 91.7 for florbetapir in differentiating AD patients from NCs, and a sensitivity of 89.3%, a specificity of 87.6%, and a diagnostic OR of 69.9 for florbetaben. There were insufficient data to complete analyses for flutemetamol. Conclusions Results suggest favorable sensitivity and specificity of amyloid imaging with fluorine 18–labeled tracers in AD. Prospective studies are required to determine optimal imaging analysis methods and resolve outstanding clinical uncertainties.

【 授权许可】

Unknown